Craniosynostoses: Clinical Trials

7 trials for Craniosynostoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7
Phase 21Completed 1

Follow Craniosynostoses: new trials by email Literature Review of Craniosynostoses trials Research Report on Craniosynostoses

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
Phase 1CompletedJanssen Pharmaceutical K.K.52023-03-032026-11-03
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
E7090, Fulvestrant, Exemestane - Breast Neoplasms
Phase 1CompletedEisai Co., Ltd.512020-10-092026-07-17
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma
Phase 1 / Phase 2CompletedBasilea Pharmaceutica952019-08-022023-10-13
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
Pemigatinib - Solid Tumors
Phase 1CompletedIncyte Corporation442017-08-012020-05-29
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
BGJ398, BYL719 - Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1CompletedNovartis Pharmaceuticals622013-10-012020-12-09
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3 - Tumor or Lymphoma
Phase 1CompletedJanssen Research & Development, LLC1882012-06-152025-02-03
Amicar Pharmacokinetics of Children Having Craniofacial Surgery
Epsilon-Aminocaproic Acid - Craniosynostosis
Phase 1CompletedPaul Stricker182009-05-012012-11-01

Narrower conditions

Acrocephalosyndactylia (6)  ·  Breast Neoplasms (2)  ·  Neoplasms (2)  ·  Urinary Bladder Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Lymphoma (1)  ·  Small Cell Lung Carcinoma (1)

Broader conditions

Bone Diseases (7)  ·  Bone Diseases, Developmental (7)  ·  Congenital Abnormalities (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Craniofacial Abnormalities (7)  ·  Dysostoses (7)  ·  Musculoskeletal Abnormalities (7)  ·  Musculoskeletal Diseases (7)  ·  Synostosis (7)  ·  Limb Deformities, Congenital (6)  ·  Syndactyly (6)  ·  Neoplasms by Site (5)  ·  Neoplasms (4)  ·  Breast Diseases (2)

Interventions

Alpelisib (1)  ·  Aminocaproic Acid (1)  ·  Fulvestrant (1)  ·  atezolizumab (1)  ·  derazantinib (1)  ·  erdafitinib (1)  ·  exemestane (1)  ·  infigratinib (1)  ·  pemigatinib (1)

Sponsors

Basilea Pharmaceutica (1)  ·  Eisai Co., Ltd. (1)  ·  Incyte Corporation (1)  ·  Janssen Pharmaceutical K.K. (1)  ·  Janssen Research & Development, LLC (1)  ·  Novartis Pharmaceuticals (1)  ·  Paul Stricker (1)

Countries

United States (4)  ·  France (3)  ·  Japan (3)  ·  Spain (3)  ·  Australia (2)  ·  Canada (2)  ·  Germany (2)  ·  Italy (2)  ·  South Korea (2)  ·  Switzerland (2)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Netherlands (1)

Top investigators

Ekaterine Asatiani, MD (1)  ·  Paul Stricker, MD (1)

Results publications

PMID 26324363, PMID 31088831, PMID 31280362, PMID 38627238

NIH funding

2019 (1)